8-K current report · filed Jul 23, 2026

UNITED THERAPEUTICS Corp (UTHR) 8-K Current Report: July 23, 2026

Item 5.02Item 7.01Item EX-99.1UTHR overview

Short answer

UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 13 members with Victor Dzau, M.D. appointed as director on July 22, 2026.

UNITED THERAPEUTICS Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded to 13 members with Victor Dzau, M.D. appointed as director on July 22, 2026
  • No initial committee assignment, limiting immediate committee-level influence
  • Equity awards total 730 restricted stock units and 2,300 stock options under the 2026 Stock Incentive Plan
  • Appointment includes standard director compensation and indemnification arrangements
  • No reportable related-party transactions exceeding $120,000 involving Dr. Dzau

Item 7.01 · Regulation FD Disclosure

  • Press release announces Dr. Dzau’s appointment
  • Appointment represents a leadership or governance change requiring investor review of Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Victor Dzau appointed to United Therapeutics’ board on July 22, 2026
  • High-profile healthcare leadership adds expertise in biomedical research, healthcare systems, and organ-transplant innovation
  • Appointment supports the company’s board refreshment and organ-alternatives strategy
  • No compensation, committee assignment, or ownership terms disclosed in the announcement

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other UNITED THERAPEUTICS Corp 8-K filings

Get the next UTHR 8-K as it lands

Follow UTHR for push alerts, or ask the research agent what this filing means.